Pfenex — Investor Presentation (February 2015)
21 slides from Pfenex's investor presentation, Feb 10, 2015
Slide 1: Corporate Presentation
Exhibit 99.2 Innovative Solutions for Global Health Corporate Presentation
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation (“Presentation”) contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our management’s beliefs and assumptions and on information currently available to management. These forward-lo
Slide 3: Investment Highlights
Investment Highlights • Biosimilar developer with patented protein production and analytics platform – Validation through industrial experience and collaborations with big pharma – 12 products in development pipeline 8 biosimilars and 1 peptide generic 3 vaccine candidates • Lead product PF582 – bio
Slide 4: Pfenex Pipeline
Pfenex Pipeline 3 *PF582 in collaboration with Hospira
Slide 5: Why Biosimilars Now?
Why Biosimilars Now? • Market opportunity is significant – Patent cliff: by 2020, biologic products representing approximately $100 billion of aggregate 2013 product sales will have become available globally – Favorable Pricing: 2010 discounts on certain biosimilars in EU member states ranged betwee
Slide 6: Pfenex Expression Technology
- Pfenex Expression Technology Problem: Traditional techniques = trial and error protein strain selection - Solution: Pfenex Expression Technology Current Protein Production Process: Pfenex Platform: Thousands of Parallel Experiments Handful of Experiments – Trial & Error Faster, Scalable, Higher Qu
Slide 7: Optimizing the Expression Universe
Optimizing the Expression Universe • Let the biology dictate the Goal: High Quality, High best conditions Titer – High yield – High quality Traditional: – Thus, low-cost production Trial and Error • Speed to solution encompasses taking guesswork out of the protein production paradigm • Pfe-nex Expre
Slide 8: Characterization is Essential to Accessing Biosimilar Pathways
Characterization is Essential to Accessing Biosimilar Pathways • Bioanalytical expertise creates robust characterization • FDA 351(k) and CHMP 437/04 both heavily emphasize bioanalytics • Extensive in-house analytical capabilities Structure Folding Activity Purity Yield 7
Slide 9: PF582: Biosimilar to Lucentis (ranibizumab)
PF582: Biosimilar to Lucentis (ranibizumab) • PF582 has the potential to disrupt the growing retinal disease market – Branded Lucentis: $4.3 billion in 2013 – Lucentis label extrapolation (including DME, RVO) enables broad access • We believe PF582 is the most advanced Lucentis biosimilar in develop
Slide 10: PF582: Hospira Collaboration
PF582: Hospira Collaboration • $342 million in combined upfront and potential milestone payments – $51 million upfront payment and $291 m in potential milestone payments • Tiered double digit royalties on net sales • Split phase 3 clinical trial costs – Pfenex costs capped at $20 million, $10 millio
Slide 11: PF582 Launches to Follow IP Expiry Roadmap
PF582 Launches to Follow IP Expiry Roadmap Country IP Status Current Open Q2 2018 Q2 2020 Jan 2022 Cumulative 2013 Sales (IMS Health) $65MM $471MM $2B $1.7B $4.2B 10
Slide 12: PF708: Generic to Forteo
PF708: Generic to Forteo® • Forteo (teriparatide) indicated for treatment of high fracture risk osteoporosis – Reference product made by E. coli fermentation – 2013 sales $1.25 billion • Generic regulatory approval pathway for PF708 – Latest to expire Orange Book-listed Forteo patent in 2019 • Pfene
Slide 13: Strides Joint Venture (JV)
Strides Joint Venture (JV) • Strides collaboration: cost effective progression of six biosimilars in Pfenex pipeline • Global commercialization of partnered products • Terms provide efficient product development progression – Pfenex responsible for creating protein production engine, process develop
Slide 14: PF530: Biosimilar to Betaseron
PF530: Biosimilar to Betaseron® • Betaseron (interferon beta-1b): indicated to reduce relapse number in multiple sclerosis patients – Sales of $1.4 billion in 2013 • We believe PF530 is the most advanced Betaseron biosimilar in global development • Phase 1 trial PF530 v. Betaseron: expected to initi
Slide 15: Vaccine Strategy Focused on Value Creation – Fully Funded by US Government
Vaccine Strategy Focused on Value Creation – Fully Funded by US Government Anthrax (rPA): Malaria: • >$45MM in awards from BARDA and • >$8.5MM in awards from NIH/NIAID for NIH (NIAID) for anthrax vaccine (3 the development of a better malaria programs) vaccine • Target market is the first responders
Slide 16: IP Protects Platform and Products
IP Protects Platform and Products Platform and Toolbox Products 10 patent families 7 patent families 80 issued/allowed 10 issued/allowed (8 U.S., 34 in EPO countries) (3 U.S., 3 in EPO) Biosimilar Promoters Secretion Leaders Production Auxotrophic Expression Microbial Toxin Markers Plasmids Producti
Slide 17: Selected Upcoming Milestones
Selected Upcoming Milestones Expected Event Timing Phase 1b/2a trial completion 1Q15 PF582 - Ranibizumab Manufacturing/technology transfer to Hospira 2015 biosimilar (Lucentis®) Initiate Phase 3 equivalence trial of PF582 vs. Lucentis in wet AMD 2016 PF708 - Teriparitide generic Initiate ANDA-enabli
Slide 18: Investment Highlights
Investment Highlights • Biosimilar developer with patented protein production and analytics platform – Validation through industrial experience and collaborations with big pharma – 12 products in development pipeline 8 biosimilars and 1 peptide generic 3 vaccine candidates • Lead product PF582 – bio
Slide 19: Appendix
Appendix PFEnex,
Slide 20: Overview of US/EU Biosimilar Regulation
Overview of US/EU Biosimilar Regulation US Biosimilar Regulatory Path EU Biosimilar Regulatory Path • 351(k) U.S. biosimilar approval pathway established in • CHMP/437/04 biosimilar approval pathway established 2010 in 2005 – Five FDA guidance documents provide additional – Biosimilar guidance on qu
Slide 21: The Pfenex Toolbox
The Pfenex Toolbox Thousands of unique components can be seamlessly integrated to enable rapid strain engineering for optimal protein production accelerating proof of concept product development and long term cost of goods advantage 20